IN THE GLEAMING laboratories of America's pharmaceutical giants, scientists routinely perform miracles. Yet the legal framework governing their endeavors has, for nearly four decades, operated under what critics call an extraordinary exemption from market forces. Now, a proposed legislation threatens to upend this arrangement, sending tremors through boardrooms from New Jersey to California. The "Restore Integrity in Vaccine Development Act" aims to dismantle a cornerstone of American pharmac...